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Abstract: N utrient excess enhances glucose-dependent insulinotropic polypeptide (GIP) secretion, 
w hich m ay in turn contribute to the developm ent of liver steatosis. We hypothesized that elevated 
GIP levels in obesity m ay affect m arkers of liver in jury through m icroRN A s. The study involved 
128 subjects (body m ass index (BM I) 25 -40 ). Fasting and postprandial GIP, glucose, insulin, and 
lipids, as w ell as fasting alanine aminotransferase (ALT), y-glutam yltransferase (GGT), cytokeratin-18, 
fibroblast grow th factor (FG F)-19, and FGF-21 w ere determ ined. TaqM an low  density  array w as 
used for quantitative analysis of blood m icroRN As. Fasting GIP w as associated w ith ALT [p = 0.16 
(confidence interval (CI): 0.01-0.32)], triglycerides [p = 0.21 (95% CI: 0.06-0.36], and FGF-21 [p = 0.20 
(95%CI: 0.03-0.37)]; and postprandial GIP w ith GGT [p = 0.17 (95%CI: 0.03-0.32)]. The odds ratio for 
elevated fatty  liver index (>73% ) w as 2.42 (95%CI: 1 .02-5.72) for h igh GIP versus low  GIP patients. 
The m iRNAs profile related to a high GIP plasm a level included upregulated m iR-136-5p, miR-320a, 
m iR-483-5p, m iR-520d-5p, m iR-520b, m iR-30e-3p, and m iR-571. Analysis of the interactions of these 
m icroRNAs w ith gene expression pathways suggests their potential contribution to the regulation of 
the activity of genes associated w ith  insulin resistance, fatty acids m etabolism , and adipocytokines 
signaling. Exaggerated fasting and postprandial secretion of G IP in  obesity  are associated w ith  
elevated liver damage markers as w ell as FGF-21 plasm a levels. Differentially expressed microRNAs 
suggest additional, epigenetic factors contributing to the g u t-liver cross-talk.
Keywords: GIP; obesity; m iRNA; liver steatosis; FGF-21; FGF-19; cytokeratin-18; gut-liver cross-talk
1. Introduction
G lucose-dependent insulinotropic polypeptide (GIP) is an intestinal horm one secreted from  
enteroendocrine K  cells, w ith a broad range of physiological actions. As an incretin horm one, G IP is 
released w ithin minutes upon intake of meal and, in the presence of elevated blood glucose, potentiates 
insulin secretion [1]. Several nutritional factors, including meal size, diet com position, glycem ic index, 
or type of fat, can affect G IP secretion [2,3 ]. C hronic exposure to a h igh-fat d iet in the presence of 
elevated blood glucose increases the expression of GIP in the gut [4 ], and induces K cell hyperplasia [5 ]. 
M echanism s that lead to the secretion of incretin horm ones are not fully understood, but involve taste
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receptors, G-protein coupled receptors (e.g., Fatty Acid Binding Protein 5 (FABP5)), sensing fatty acid 
derivatives, exposure to bile acids, and the microbiome [6,7]. Fat ingestion is also a strong stim ulant of 
GIP release, bu t in  the state of eu- or hypoglycem ia, GIP does not influence insulin, bu t stim ulates 
g lucagon secretion, suggesting that G IP supports the m aintenance of optim al glucose levels [8,9 ]. 
Reduced incretin effect is a feature of type 2 diabetes (T2D) [10]. G IP receptor dow n-regulation and 
desensitization have been suggested as potential causes of the dim inished insulin response to GIP in 
T2D [11,12].
G IP also acts directly on adipocytes, im m une cells, endothelial cells, bone cells, and neuronal 
cells [13] . Therefore, p leiotropic GIP actions involve the follow ing: control of beta cell function 
and survival, prom otion of nutrient storage and inhibition of lipolysis in  adipose tissue, effect on 
inflam m atory cytokines secretion, regulation of bone m arrow  cells' differentiation, and regulation of 
bone m etabolism  [14- 17]. Selected studies indicate that d isturbed GIP signaling in obesity  as w ell 
as in diabetes is associated w ith  im pairm ent of fat m etabolism  and liver fat accum ulation, bu t the 
m echanism s are still poorly  understood [3,18]. As the receptor for GIP (GIPR) is not found to be 
expressed on hepatocytes, the suggested relation of GIP w ith fatty liver disease m ay involve its direct 
and indirect influence on n utrients' m etabolism , as w ell as interactions w ith  other endocrine factors 
regulating liver function.
Non-alcoholic fatty liver disease (NAFLD) refers to a spectrum  of disorders ranging from simple 
hepatic steatosis to more severe m anifestations, including non-alcoholic steatohepatitis (NASH), w hich 
can progress to fibrosis, cirrhosis, and liver failure. Subjects w ith  N A FLD  and N A SH  typically have 
elevated circulating concentrations of m arkers of liver injury, including alanine am inotransferase 
(ALT), aspartate am inotransferase (AST), and y-glutam yltransferase (GGT) [19]. If biopsy or im aging 
of the liver are not possible, these m arkers of liver injury serve as easy, reliable surrogate m easures of 
N AFLD [20]. For practical purposes, som e algorithm s (e.g., fatty liver index; FLI) w ere developed for 
the selection of subjects at greater risk for hepatic steatosis in the general population, based on routine 
m easurem ents in clinical practice [21].
For diagnosis and staging of N ASH, hepatocyte apoptosis markers, such as cytokeratin-18 (CK-18), 
can be useful [22]. C ytokeratin-18, being a m ajor interm ediate filam ent protein in  hepatocytes, is 
cleaved by caspase 3  and released into the blood stream  by hepatocytes undergoing apoptosis. The 
fragmented CK-18 (M30) serum level is associated w ith the presence of hepatic fibrosis. Cytokeratin-18 
is an em erging risk factor and could be applied as a valuable index for non-invasive d iagnosis of 
steatohepatitis, although it is not introduced into routine laboratory tests.
The d iscovery of endocrine fibroblast grow th factors (FGF), including FG F-21 and FG F-19, has 
uncovered new  m echanism s that regulate m etabolism  and lipid hom eostasis, and has provided 
potential therapeutic targets for type 2  diabetes, obesity, and hepatic steatosis [23]. A fter extensive 
research over the past few  years, hepatokine FG F-21 has em erged as a prom ising diagnostic m arker 
for an accurate and non-invasive diagnosis o f N A FLD  [24,25]. FGF-21 is know n to regulate energy 
hom eostasis, glucose-lipid m etabolism , and insulin sensitivity [26], though it is unclear w hich of these 
m etabolic functions of FGF-21 underlie the association of plasm a FGF-21 level and NAFLD. FGF-19 is 
produced and released from enteroendocrine cells and reaches the liver through the portal vein, where 
it interacts via activation of the FGFR4-klotho com plex receptor [27]. The effects of FGF-19 in the liver 
involve suppression of de novo lipogenesis, increase of fatty acids oxidation, and suppression of bile 
acids synthesis; thereby, FGF-19 is thought to am eliorate hepatic steatosis and lipotoxicity. Activity of 
this enterokine underlies the g u t-liver axis concept [28].
In  m ost studies, the prevalence of N A FLD  is h igher in  individuals w ith  features o f m etabolic 
syndrom e including obesity, diabetes, and hypertension. The relationship of body m ass index (BM I), 
w aist circum ference, triglycerides, and m etabolic syndrom e w ith  N A FLD  is w ell docum ented [29]. 
However, there are limited data on GIP as a prognostic factor for NAFLD. A recent paper by Yamane & 
H arada [30] indicates an im portant role of G IPR signaling in adipose tissue in h igh fat d iet -induced 
insulin resistance and hepatic steatosis in vivo [30] . The above-m entioned m etabolic diseases can be
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m ediated by circulating m icroRN As (miRNAs), w hich constitute an im portant epigenetic m echanism  
for the regulation of gene expression. Extracellu lar m iRN A s constitute prom ising, clin ically-useful 
biom arkers for the N AFLD and hepatocellular carcinom a [31]. N AFLD developm ent and progression 
is also m odulated by miRNAs, which control at post-transcriptional level many com plem entary target 
m RN As, and w hose dysregulation has been show n to have predictive value in  N A FLD , as reviewed 
by D ongiovanni et al. 2018 [32]. m iRN A s are know n to interact w ith products of different genes that 
regulate lipid synthesis, glucose and fatty acids utilization, inflam m ation, and apoptosis, w hich have 
been know n to be epigenetically deregulated in N A FLD. Therefore, alteration of m iRN A  expression 
in response to nutrition and  nutrition-related  endocrine factors m ay contribute to liver steatosis. A 
recent study on the animal model underlies the role of m iRNA, regulated by diet and insulin resistance, 
in cell-to-cell com m unication betw een hepatocytes and  hepatic stellate cells, w hich m ay prom ote 
progressive N A FLD  [33]. There are very little data on circulating m iRNA in relation to plasm a incretin 
levels, and it concerns m ainly glucagon-like peptide-1 (GLP-1) not GIP [34]. U nderstanding how  
enhanced GIP secretion in obese hum ans can alter p lasm a m iRN A  profile and characterizing their 
target m RN A m ay help to elucidate potential biological m echanism s for contribution of elevated GIP 
to the developm ent of liver steatosis.
In  this study, the aim  w as to investigate w hether exaggerated secretion of G IP in obesity  m ay 
affect the m arkers o f liver in jury and liver targeted FG Fs. W e assessed the relationships of plasm a 
levels of GIP to ALT, GGT, cytokeratin-18, and FLI, as w ell as FGF-19 and FGF-21. As GIP acts mainly 
after meal ingestion, we analyzed some risk factors for the developm ent of fatty liver disease, not only 
fasting, bu t also in the postprandial state. In addition to biochem ical m arkers, the study attem pts to 
find m iRN A s as m olecular m arkers associated w ith  high plasm a G IP levels, w hich  m ay contribute 
to the risk o f fatty  liver disease. Finally, w e analyzed the roles of significantly regulated m iRN A s in 
relation to their target genes.
2. M aterials and M ethods
2.1. Subjects
The study included 128 subjects w ith  BM I exceeding the norm al range (25 -40  kg/m2), w om en 
and m en, aged 2 5 -6 5  years. A ll participants had no evidence of chronic d iseases, particularly  
liver d iseases, diabetes m ellitus, endocrine disorders, k idney dysfunction, autoim m une disease, 
and inflam m ation. Exclusion criteria included therapy w ith  horm ones, anti-inflam m atory, or other 
medicines/pharmaceuticals known to affect lipid or glucose m etabolism ; m oderate to excessive use of 
alcohol; smoking; pregnancy; or lactation. Participants were drawn from the Bioclaims study (data from 
the study are deposited in Nutritional Phenotype Database http://www.dbnp.org/nutritional-instance/). 
The study w as conducted in accordance w ith  the C ode of Ethics of the W orld M edical A ssociation 
(D eclaration of H elsinki) and w ith  the Good C linical Practice guidelines. The study protocol w as 
approved by the Bioethics C om m ittee o f the Jagiellonian University, Krakow, Poland (file num ber: 
KBET/82/B/2009 and 1072.6120.57.2017), and all individuals gave oral and w ritten  inform ed consent 
prior to inclusion in the study.
2.2. A nthropom etry M easurem ents
Body w eight, height, w aist, and hip circum ferences and blood pressure w ere m easured. Body 
com position w as estimated w ith the eight-polar bio-electrical im pedance analysis using the Segmental 
Body Com position A nalyzer TANITA BC 418 M A (Tanita Corporation, Tokyo, Japan). Ethanol intake 
w as validated by  analysis of a seven-day diary of food intake.
2.3. Sample Collection and A nalysis
Venous blood sam ples were collected through an intravenous catheter fasting and during an oral 
glucose tolerance test and m eal tolerance test into K-ED TA  tubes (Sarstedt A G  & Co. N üm brecht,
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Germany). Plasm a was separated from blood cells w ithin 30 min by centrifugation (10 min at 3000X g, 
at 4 °C). For biochem ical tests (except free fatty acids (FFAs)), plasma samples were im m ediately stored 
at - 8 0  °C  until analyzed. For m icroR N A  analysis, venous blood w as collected into PAXgene Blood 
RNA Tubes (Becton D ickinson, Bedford, NJ, USA) and stored at - 8 0  °C until analyzed.
2.4. Oral G lucose Tolerance Test (OGTT)
An oral glucose tolerance test w as perform ed according to World Health Organization/International 
D iabetes Federation  guidelines. Tests w ere perform ed during m orning hours (08:00-11:00) after a 10 h 
overnight fast. Blood sam ples w ere collected before glucose load (fasting) and then 30, 60, 90, and 
120 m in after the ingestion of 75 g of glucose dissolved in 250 mL of water.
2.5. M eal Tolerance Test (MTT)
The day before the test, participants ate a last low -fat m eal before 6  p.m . (tw o slices of bread 
w ithou t any fatty products, and unsw eetened tea). Test m eals w ere given at 07:30 and postprandial 
studies w ere perform ed from  07:30 to 13:30. The test m eal contained light bread— 50 g, butter— 20 g, 
cream  cheese— 60 g, pork  loin  roast— 100 g, and m ayonnaise— 40 g. This m eal contained 73%  fat, 
16% protein, and 11% carbohydrates, w ith  a caloric value of 1018 kcal (the com position of M TT w as 
described in detail previously [35]). Venous blood samples were collected before the meal (fasting) and 
postprandially 2, 4, 6, and 8 h after the test meal.
2.6. Biochemical Tests
A ll biochem ical tests w ere perform ed in fasting plasm a sam ples. Glucose, insulin, and G IP w ere 
m easured additionally in blood sam ples collected during the O G TT and GIP, triglycerides, and free 
fatty acids (FFAs) w ere also m easured in blood sam ples collected during MTT.
Free fatty  acids concentrations w ere m easured im m ediately  in  fresh plasm a by an enzym atic 
quantitative colorim etric m ethod (Roche D iagnostics G m bH , Berlin , G erm any). P lasm a glucose, 
total cholesterol, HDL-cholesterol, and triglycerides w ere assayed by autom ated, standard enzym atic 
colorimetric m ethods using the M axM at Analyzer (MaxM at SA, M ontpellier, France). LDL-cholesterol 
was calculated using the Friedewald formula. Serum insulin was determined by the im munoradiometric 
m ethod (D IA source Im m unoassys, Louvain-la-N euve, Belgium ) and read using the gam m a counter 
(LKB Instruments, Victoria, Australia). Hom eostasis model assessment of insulin resistance (HOMA-IR 
index) w as calculated as a ratio (fasting glucose (m m ol L - 1) X fasting insulin  (pU  m L - 1 )]/22.5). To 
m easure p lasm a G IP concentrations, the ELISA  k it (H um an GIP [Total] 96-W ell Plate A ssay (EM D  
M illipore, St Charles, M O , USA)) w as used. The lim it detection of the G IP  assay used w as 8.2 pg/mL. 
Activities of ALT and GGT w ere assayed in a clinical laboratory by the standard biochem istry method 
using an automated analyzer. The fatty liver index (FLI) is based on scoring algorithm  involving BM I, 
w aist circum ference, triglycerides, and GGT, and w as calculated according to Bedogni et al. (2006).
FLI = (e 0.953*loge (triglycerides) + 0.139*BMI + 0.718*loge (GGT) + 0.053*waist circumference -  15.745)/(1 + 
e 0.953*loge (triglycerides) + 0.139*BMI + 0.718*loge (GGT) + 0.053*waist circumference -15.745) * 100
C ytokeratin-18 concentrations w ere determ ined by  the M 30 A poptosense ELISA  (PEVIVA, 
VIVALAVID A, Sundbyberg, Sveden), w hich  m easures the levels of soluble caspase-cleaved keratin  
18 (CK -18) fragm ents containing the K 18A sp396 neo-epitope. The assays for FG F-19 and FGF-21 
em ployed the quantitative ELISAs (Human FGF-19 Quantikine ELISA, and Hum an FGF-21 Quantikine 
ELISA , respectively, R & D  System s Inc. M inneapolis, M N , U SA ). The lim it o f detection of hum an 
FGF-19 and FGF-21 im munoassays was 1.17 pg/mL and 4.67 pg/mL, w ithin-run coefficient of variation 
(CV) w as 4.83%  and 3.43%, and betw een-run CV w as 5.13%  and 7.5%, respectively.
Nutrients 2 0 2 0 ,12, 476 5 of 22
2.7. Isolation and Real-Time PCR o f  miRNA
Total RNA, including miRNA, w as isolated from plasma, using the GeneMATRIX Universal RNA 
Purification K it (EU Rx, G dansk, Poland) and RN A  quality w as assessed in an A gilent B ioanalyzer 
2100 using the RN A 6000 Nano kit (Agilent Technologies, Santa Clara, CA, USA).
R elative m iR N A  expression w as determ ined in 18 sam ples from  subjects representing the high 
GIP group (n  =  9) and low  G IP group (n  =  9). R epresentative subjects draw n from  both  groups 
w ere sim ilar according to age, sex (77%  fem ale), and BM I, w hile they reflected the sam e differences 
between the two groups they represented (fasting and postprandial GIP levels and liver injury markers). 
For relative quantification of m iRN A , TaqM an low  density  array (TLD A ) w as used (Therm o Fisher 
Scientific, Waltham, M A, USA). Reverse transcription was performed with TaqMan M icroRN A Reverse 
Transcription K it com ponents and M egaPlex H um an Pool A and B RT prim ers. The pream plification 
step w as enabled by M egaplex™  PreAmp Prim ers and then TaqMan® Array H um an M icroRN A A+B 
Cards Set v3.0 w ere em ployed for the accurate quantitation of 754 hum an m icroR N A  by real-tim e 
PCR. The arrays w ere run on the 7900H T Fast Real-Tim e PC R  system  (Therm oFisher, W altham , M A, 
U SA ). A ccording to recom m endations [36], a m iRN A  w as considered non-inform ative if C T values 
were >35 in >80% of samples. Relative miRNA levels were expressed as fold of change (fold of change 
(RQ) = geom etric m ean 2 (-ACt high GIP) / geometric m ean 2(-ACt lowGIP)), w here U6 snRNA w as used as 
endogenous control.
The know n m iRN A  gene targets w ere extracted u sing the m irPath v.3 D IA N A  TO O LS. The 
m iR N A -gene interaction netw ork w as generated through Cytoscape w ith ClueGO  [37].
2.8. Statistical Analyses
D ata distribution w as assessed by Shapiro-W ilk test, w hich indicated that data w ere usually not 
norm ally distributed. H om ogeneity of variance w as confirm ed by Levene's test. For anthropom etric 
and biochem ical param eters, data are presented as the m edian and low er and upper quartile (Q2 
(Q 1-Q 3)). The tw o-sided M an n -W h itn ey  U test w as applied for com parison of these variables 
between two groups w ith low or high GIP. Data distributions, power of tests, confidence intervals, and 
other statistical calculations w ere perform ed using the Statistica softw are (StatSoft, v.13 PL). Logistic 
regression analysis w as used to evaluate the contributions of high plasm a GIP to the risk for elevated 
liver markers. Odds ratios (ORs) and 95% confidence intervals (95% CIs) for high GIP were calculated. 
L inear regression analysis w as used to evaluate the association betw een fasting plasm a GIP, G IP 
response to MTT, GIP response to OGTT, and fatty liver risk factors. Variance inflation factors (VIFs) 
w ere presented to quantify how m uch the standard errors of the estim ated coefficients are inflated by 
the existence of correlation among the predictor variables. Areas under curves (AUCs) were calculated 
w ith  the trapezoidal rule. The relative expression levels of m iR N A  w ere reported as the m eans and 
standard deviations. Tw o-sam ple, tw o-tailed Student's t-test com paring the 2 (-ACt) values of the two 
groups w as perform ed for p  value calcu lation (D ataA ssist Softw are v.3.01). p  < 0.05 w as considered 
statistically significant and differentially expressed m iRNA were used for signaling pathways analysis 
by  Cytoscape (v.3.4.0).
3. Results
Associations of plasma fasting and postprandial GIP levels w ith factors that may influence NAFLD 
were investigated in this study. For this purpose, we analyzed liver injury markers (ALT, GGT, CK-18), 
liver targeted fibroblast grow th factors (FG F-19, FG F-21), as w ell as circulating m iRN A  profile in 
relation to plasm a G IP concentrations.
3.1. Baseline Characteristics o f  Subjects
The baseline characteristics of the subjects are sum m arized in Table 1.
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Table 1. Characteristics of subjects included in the study, comparison of groups according to fasting 
plasma glucose-dependent insulinotropic polypeptide (GIP) level.
All (n = 128) Low GIP (n = 85) High GIP (n = 43)
Median (Q1; Q3) Median (Q1; Q3) Median (Q1; Q3) P *
Sex (% of female) 74% 81% 61% 0.021 §
Age (yrs) 47 (39; 57) 46 (39; 57) 54 (41.5; 58) 0.134
BMI (kg/m2) 32.28 (29.84; 34.77) 32.03 (28.87; 34.55) 32.97 (31.13; 36.02) 0.065
Waist circumference (cm) 100 (94; 110) 99 (93; 108) 110 (97; 117) 0.009
Women 98 (93; 106) 96 (91; 103) 100 (95; 110) 0.052
Men 114 (106; 118) 114 (107; 116) 116 (105; 121) 0.505
WHR 0.88 (0.82; 0.96) 0.85 (0.81; 0.93) 0.91 (0.84; 0.98) 0.016
Women 0.84 (0.81; 0.90) 0.83 (0.8; 0.89) 0.87 (0.84; 0.91) 0.051
Men 0.99 (0.89; 1.51) 1.01 (0.98; 1.04) 0.98 (0.96; 1.03) 0.263
Body fat (%) 38.30 (33.50; 42.00) 38.1 (33.58; 42.05) 38.8 (32.6; 42) 0.959
Systolic blood pressure (mmHg) 130 (120; 140) 125 (120; 134.5) 130 (120; 140) 0.184
Diastolic blood pressure (mmHg) 84 (80; 90) 82 (80; 90) 90 (80; 90) 0.111
Fasting glucose (mmol/l) 5.1 (4.8; 5.6) 5.0 (4.8; 5.4) 5.6 (5.0; 6.0) <0.001
Fasting insulin (pIU/mL) 13.05 (9.68; 19.03) 12.4 (9.10; 18.00) 15.00 (11.40; 20.55) 0.075
HOMA-IR 2.93 (2.17; 4,56) 2.7 (2.13; 4.33) 3.68 (2.72; 5.42) 0.021
GIP (pg/mL) 26.2 (18.3; 38.5) 19.44 (15.27; 26.12) 44.86 (38.72; 53.43) <0.001
GIP AUC MTT (ng/mL*min) 347.7 (279.4; 436.9) 320.3 (248.8; 389.7) 401.0 (324.7; 573.6) <0.001
GIP AUC OGTT (ng/mL*min) 63.8 (47.6; 86.1) 60.97 (46.91; 79.73) 74.42 (58.18; 94.43) <0.013
FFA (mmol/l) 0.67 (0.52; 0.86) 0.67 (0.52; 0.83) 0.66 (0.53; 0.93) 0.714
FFA AUC MTT (mol/l*min) 1.45 (1.22; 1.78) 1.41 (1.22; 1.68) 1.56 (1.17; 2.03) 0.338
TG (mmol/l) 1.24 (0.92; 1.80) 1.16 (0.90; 1.49) 1.57 (1.17; 2.28) 0.002
TG AUC MTT (mol/l*min) 3.47 (2.43; 4.89) 3.22 (2.30; 4.34) 4.19 (2.83; 5.84) 0.017
Cholesterol total (mmol/l) 5.43 (4.82; 6.07) 5.39 (4.8; 6.03) 5.46 (4.94; 6.3) 0.311
HDL-cholesterol (mmol/l) 1.28 (1.13; 1.48) 1.32 (1.16; 1.5) 1.20 (1.11; 1.32) 0.004
LDL-cholesterol (mmol/l) 3.45 (2.87; 4.13) 3.41 (2.90; 4.08) 3.54 (2.78; 4.39) 0.527
ALT (IU/l) 16.0 (12.0; 22 .0) 14.0 (11.0; 19.0) 21.0 (13.5; 30.5) 0.004
GGT (IU/l) 18.0 (12.0; 31.0) 15.0 (12.0; 25.0) 24.0 (15.3; 40.5) 0.007
Fatty Liver Index (%) 70.5 (45.1; 86.1) 57.4 (42.0; 79.1) 84.2 (66.4; 90.3) 0.000
Cytokeratin; 18 (U/l) 115.4 (86.1; 159.5) 110.8 (80.5; 148.3) 132.5 (91.1; 193.2) 0.090
FGF-19 (pg/mL) 108.8 (65.5; 178.4) 112.6 (62.8; 168.4) 104.2 (81.0; 206.2) 0.567
FGF-21 (pg/mL) 187.4 (120.2; 285.5) 165.3 (85.3; 255.4) 253.3 (154.3; 357.0) 0.007
* Except the first row, the significance of all differences were tested using the Mann-Whitney U test; § the significance 
of differences in the percentage of female was tested using the Chi-square frequency test; values are median 
(lower quartile; upper quartile), except sex values expressed as percentage of female, (n = 128). Abbreviations:
High GIP—group of subjects with fasting plasma GIP level >66th percentile, Low GIP—group of subjects with 
plasma fasting GIP level <66th, BMI—body mass index, WHR—waist-to-hip ratio, HOMA-IR—homeostatic model 
assessment, GIP—glucose-dependent insulinotropic polypeptide, AUC—area under curve, MTT—meal tolerance 
test, OGTT—oral glucose tolerance test, FFA—free fatty acids, TG—triglycerides, ALT—alanine aminotransferase,
GGT—gamma-glutamyltransferase, FGF-19—fibroblast growth factor-19, FGF-21—fibroblast growth factor-21.
All subjects (95 w om en and 33 m en) included in the study were obese or overweight, the m edian 
BMI was 32.28 (Q 1-Q 3: 29.84-34.77) kg/m2, the m edian body fat w as 38.30% (Q 1-Q 3: 33.50% -42.00% ). 
Fasting plasm a levels of GIP ranged from 5.36 pg/mL to 144.97 pg/mL, w ith a m edian of 26.16 pg/mL 
(Q 1-Q 3: 18.29-38.54). Secretion of G IP in response to glucose (O G TT) or m eal (M TT) challenge 
measured as AUC values was also very diverse w ithin this cohort (Table 1). ALT activity in the majority 
of subjects rem ained w ith in  the norm al range (< 40 IU/L), and only 5/128 subjects (4%) had higher 
plasm a ALT activity. M edian G G T activity  w as 18 IU  and 85%  of subjects had G G T <40 IU/L. The 
m edian of cytokeratin-18 fragm ents levels w as 115 (Q1; Q3: 86-159). In serum  from  28/128 subjects 
(22%), CK-18 levels w ere above 180 U/L, although in 90% of all subjects CK-18 values did not exceed 
296 U/L. Fatty liver index (FLI) values above 60, recognized as predictive for liver steatosis, were found 
in 71/128 subjects (55%) from our cohort.
3.2. Association o fP lasm a GIP w ith Fatty Liver Risk M arkers
In the whole cohort of obese subjects, we observed a correlation of fasting GIP with ALT (Spearman 
correlation coefficient r = 0.22, p  = 0.015) and w ith  FLI (Spearm an correlation coefficient r = 0.27,
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p  = 0.002). To exam ine in detail the association of p lasm a G IP w ith  fatty  liver risk m arkers, linear 
regression m odels w ere tested (Table 2).
Table 2. Linear regression models of the association between fasting and postprandial GIP plasma 






Fasting GIP 0.21 (0.06-0.36) 0.20 (0.04-0.35)
R2 18% 19%
VIFs <1.0 <1.3
GIP AUC MTT 0.21 (0.05-0.37) 0.20 (0.04-0.36)
R2 21% 24%
VIFs <1.0 <1.2
















Fasting GIP 0.20 (0.03-0.37) 0.22 (0.05-0.4)
R2 7% 10%
VIFs <1.1 <1.3
GIP AUC MTT 1.14 (-0.04-0.31) 1.17 (-0.01-0.34)
R2 5% 7%
VIFs <1.1 <1.3
Model 1 adjusted for sex and age (n = 128); model 2 adjusted for sex, age, BMI, and fasting glucose (n=128);
R2—coefficient of determination expressed in %; VIF—variance inflation factor. Abbreviations: GIP AUC MTT—area 
under curve of GIP concentration during meal tolerance test, GIP AUC OGTT—area under curve of GIP concentration 
during oral glucose tolerance test, TG AUC MTT—area under curve of serum triglycerides concentration during 
meal tolerance test, ALT—alanine aminotransferase, GGT—gamma-glutamyltransferase.
This analysis revealed that the fasting plasm a GIP level w as significantly associated w ith  ALT 
(independently of sex and age— m odel 1), w ith fasting triglycerides, and w ith FGF-21 (independently 
of sex, age, BM I, and fasting glucose— m odel 2). The standardized ß-coefficient indicates that the 
increase of fasting GIP by 22 pg/mL is associated with the increase of FGF-21 by 34 pg/mL. An enhanced 
GIP response to high-fat meal intake (GIP AUC MTT) was found as a factor independently influencing 
not only fasting, bu t also postprandial triglycerides levels and, interestingly, h igher G G T activity 
in both  m odels. G IP response to glucose oral intake (G IP  A U C  O G TT) w as also related to fasting 
triglycerides, w hich  provide consistent data for the association of circulating GIP w ith  triglycerides 
(Table 2). In all regression m odels, VIF was low (VIF < 2), indicating that there w as no multicolinearity.
In separate logistic regression models adjusted for age and sex, subjects in the upper tertile of GIP 
w ere at significantly increased risk for elevated ALT com pared w ith those in the low er tertiles: ALT > 
23 IU/L OR 3.16 (95% CI 1.23-8.13); ALT > 31 IU/L, O R 4.82 (95% CI 1.46-15.91) (Table 3 ).
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Table 3. Contributions of high plasma GIP level (odds ratios and 95% confidence interval (CI)) to the 
risk of elevated liver markers—logistic regression analysis.
High GIP
OR (95% CI) 
for ALT >  23 IU/l
OR (95% CI) 
for ALT > 31 IU/l
O R (95% CI) 
for FLI >  73%
O R (95% CI) 
for FG F-21 >  M edian
O R (95% CI) 
for FG F-21 >  3rd Tertile
M odel 1 
(adjusted fo r  age and sex) 
M odel 2  
(ad justed for age, sex, 





















Odds ratios (OR) and 95% CI (confidence interval) here indicate changes associated with upper tertile of GIP; 
* p < 0.05 (n = 128); Abbreviations: High GIP—group of subjects with fasting plasma GIP level >66th percentile; 
ALT—alanine aminotransferase, FLI—fatty liver index, BMI—body mass index.
After further adjustment for BMI and fasting glucose, the associations of fasting plasm a GIP with 
elevated ALT rem ained significant: ALT > 23 IU/L O R  3.11 (95%  CI 1 .13-8 .57); ALT > 3 1 IU/L, O R 
4.31 (95% CI 1.20-15.43). FGF-21 values w ere dichotom ized using 187 pg/mL (median) or 254 pg/mL 
(3rd tertile) as cut-off points for logistic regression analysis. The h igh  plasm a G IP (>3rd tertile) w as 
also an independent factor for increased risk (2.46 (1 .05-5 .84)) of h igh plasm a FGF-21 (>3rd  tertile) 
(Table 3) . Com pared w ith the participants in the two low er tertiles of GIP, the adjusted (age, sex) O R 
for elevated FLI (>73%) was 2.42 (95% CI 1.02-5.72) for those in the upper tertile of GIP. Moreover, OR 
for significantly elevated FLI (>87% ) w as 1.04 (95%  CI 1 .01-1.07) w ith  the increase of fasting G IP by 
every 1 pg/mL. This association was adjusted for age, sex, BMI, and fasting plasma glucose levels. The 
results show ed that fasting plasm a GIP levels predict elevated liver m arkers— ALT, FLI, and FGF-21.
3.3. Fatty Liver Risk M arkers in H igh GIP Subjects
O n the basis of the fasting plasm a G IP level, two groups w ere selected from am ong the patients 
w ith  excess body w eight. The cu t-off p oint w as set at 34 pg/mL, w hich  states the 66th percentile of 
p lasm a G IP concentration in  this cohort (Table 1). These tw o groups (high G IP versus low  G IP) did 
n ot differ in  term s of age, BM I, and body fat content. How ever, the subjects w ith  h igher plasm a GIP 
had increased w aist circum ference and w aist-to-hip ratio (W HR), indicating visceral adiposity. Even 
concerning the difference in gender distribution in  both groups, the trend w as also observed in the 
w om en subgroup, w hich constitutes the m ajority of subjects. The tendency for abdom inal obesity in 
w om en w ith high GIP w as expressed as greater w aist circumference (Q2 (Q3-Q 1): 100 (95-110) versus 96 
(91-103), p = 0.052) and W H R (Q2 (Q3-Q 1): 0.87 (0.84-0.91) versus 0.83 (0.80-0.89), p  = 0.051). High GIP 
group w as characterized by elevated fasting glucose, w ith im paired fasting glucose (5.6-6.9 mmol/L) 
in half of the cases, and enhanced insulin resistance H O M A -IR  (Q2 (Q 3-Q 1): 3.68 (2 .72-5 .42) versus 
2 .70 (2 .13-4 .33), p  = 0.021). A lthough fasting plasm a total cholesterol, LD L-cholesterol, and FFA 
w ere com parable in both groups, subjects w ith high plasm a GIP show ed an unfavorable lipid profile 
regarding elevated triglycerides (Q2 (Q 3-Q 1): 1.57 (1 .17-2 .28) versus 1.16 (0 .9-1 .49), p  = 0.002) and 
decreased H D L-cholesterol (Q2 (Q 3-Q 1): 1.32 (1.16-1.5) versus 1.20 (1.11-1.32), p  = 0.004), com pared 
w ith those w ith low GIP levels.
G IP release in  response to a h igh-fat m eal as w ell as in response to oral glucose load (reflected 
by GIP A U C  O G TT and G IP A U C  M TT) w as significantly greater in the h igh G IP group com pared 
w ith  the low  GIP group (Table 1). E levated postprandial GIP levels w ere accom panied by increased 
glucose and insulin levels in response to the m eal, as show n by glucose AUC M TT (Q2 (Q 3-Q 1): 9.89 
(9.46-10.44) versus 9.28 (8.86-9.92), p = 0.001) and insulin AUC M TT (Q2 (Q 3-Q 1): 43.10 (32.69-63.48) 
versus 34.68 (25 .55-51 .83), p  = 0.028). O bese subjects characterized by  high GIP levels also show ed 
greater triglycerides response to a high-fat m eal, reflected by  significantly higher TG values, at every 
tim e point after m eal ingestion during MMT: 2 h  (Q2 (Q 3-Q 1): 2.31 (1.47-3.08) versus 1.9 (1.45-2.46), 
p  = 0.048); 4 h  (Q2 (Q 3-Q 1): 2.60 (1 .90-3 .76) versus 2.07 (1.40-3 .00), p  = 0.032); 6 h  (Q2 (Q 3-Q 1): 2.13 
(1.20-2.82) versus 1.44 (1.05-2.30), p  = 0.015); 8 h  (Q2 (Q -Q 1): 1.57 (0 .97-2 .33) versus 1.09 (0 .79-1.53), 
p  = 0.006). The above results point to the disturbed postprandial glucose and lipid m etabolism  in high 
GIP obese patients.
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A lanine am inotransferase, GGT, and cytokeratin-18 fragm ents w ere determ ined as biochem ical 
m arkers o f liver in jury  and the fatty liver index w as calculated. The percentage o f subjects w ith FLI 
>60 in the high GIP group w as 74%, w hereas in the low  GIP group, it w as 46%  (p < 0.05). The plasm a 
activity  o f both  liver enzym es ALT and GGT, as w ell as calculated FLI, w as significantly elevated in 
subjects w ith  GIP >66th percentile (Table 1, Figure 1a-c ) . In this group, only a tendency for elevated 
C K -18, a m arker o f liver cells apoptosis, w as observed (Q2 (Q 3-Q 1): 132.5 (91.1-193.2) versus 110.8 
(80.5-148.3, p  = 0.090), compared with the low GIP group (Figure 1d ). However, plasma CK-18 >180 IU 
w as found in 115 subjects from  the low  GIP group and 13 subjects from  the high GIP group.
Figure 1. Fatty liver risk; markers: ALT (a), GGT (b), FLI (c), cytokeratin-18 (d), FGF-19 (e), and FGF-21 
(f) in the Low GIP (n = 85) and High GIP (n = 43) groups of patients. Values are presented as median 
(line), upper and lower quartile (box), and minimum and maximum (whiskers). Significant differences 
are indicated as; * p < 0.05 (Mann-Whitney U test, Statistica softaware v.13). Abbreviations: High 
GIP—group of subjects with fasting; plasma GIP level >66th percentile, Low GIP—group of subjects with 
plasma fasting GIP level <66th, ALT—alanine aminotransferase, GGT—gamma-gletamyltransferase, 
FGF-19—fibroblast growth lactor-19, FGF-21—fibroblast growt= factor-21;
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Two liver targeted FG Fs, enterokine FGF-19 and hepatokine FG F-21, w ere also analyzed in the 
groups of obese subjects according to plasm a fasting G IP levels. There w as no difference in the 
concentration of FGF-19 between these groups (Figure 1e). In contrast, the levels of hepatokine FGF-21 
differ between both groups, being significantly higher in the high GIP group (Q2 (Q3-Q1): 253 (154-357) 
versus 165 (85-255), p  = 0.007) com pared w ith the low GIP group (Figure 1f).
3.4. M icroRN A profile in H igh GIP Subjects
Analysis of microRNA relative expression revealed the m iRNA profile related to high GIP plasma 
level in  obesity. For 754 m icroR N A s tested w ith  TLD A  in each blood sam ple, 174 types of m iRN A s 
w ere detected, and 15 m iRN A s 'were differentially expressed in  analyzed groups, including 7 up
regulated m iRN A s and 8 downregulated m iRN A s (Figure 2).
log2 (Fold Change)
Figure 2. Volcano plot shows the relative expression of microRNAs in the high GIP versus low GIP
group; fold change boundary: 1.2, p-value boundary: 0.05 (prepared using DataAssist Software v.3.01).
Relatively increased m iRNAs' expression in the high GIP patients concerns m iR-136-5p, miR-320a, 
m iR-483-5p, m iR-520d-5p, m iR-520b, m iR-30e-3p, and m iR-571; as w ell as m iR-103a-3p, m iR-218-5p, 
m iR-328-3p , m iR-489-3p , m iR-524-3p , m iR-601, m iR-1305, and m iR-1243 for relatively decreased 
m iRN A s' expression, com pared 'with low GIP patients (Figure 3).
Analysis of the interactions of differentially expressed microRNAs w ith gene expression pathways 
suggests the potential contribution of se lected m iR N A s in the regulation of the activity  of genes 
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Figure 3. Quantitative PCR (TaqMan low density array (T’L,DA)) showing the expression of microRNAs 
in the high GIP versus low GIP group. Relative miRNA lsvels are expressed as fold of change, with U6 
snRNA used as endogenous control; upregulated miRNA—black tsars, downregulated miRNA—gray 
bars (n = 18; p < 0.05; t-test, DataAssist Software v.3.01).
Figure 4. Interactions of microRNAs with gene pathways. The known miRNA gene targets were 
extracted using the mirPath v.3 DIANA TOOLS. The miRNA-gene interaetion network was generated 
through Cytoscape with ClueGO.
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Significantly upregulated m iR-320a as w ell as m iR-520b and m iR-520d-5p have the potential to 
inhibit the expression of genes involved in insulin signaling such as PIK3CA, AKT3, SHC4, SOS1, KRAS, 
and M APK1. M icroRN A-320a together w ith upregulated miR136-5p m ay inhibit PPARGC1, which is a 
crucial transcription factor regulating energy hom eostasis, fatty  acids oxidation, and m itochondrial 
biogenesis. D ow nregulated m iR-103a-3p and m iR-1305 m ay influence lipogenesis by  target genes 
FASN  and A C C A , respectively. A dditionally, the deficit of m iR-1305 m ay also result in  insufficient 
inhibition of ACSL6, leading to intensive synthesis of ceram ides, and thus linking excess nutrients and 
inflam m atory cytokines (e.g., tum or necrosis factor-a , T N F -a) to the induction of insulin  resistance. 
In the high GIP group, leptin  signaling m ay be d isturbed by  the interaction of m iR-520d w ith  the 
LEPR  gene transcript, and further by other interactions, including the following: m iR-320a w ith JA K 2 
and m iR-520b w ith  STAT3. A nother im portant target gene of m iR-520d, abu ndant in subjects w ith  
high plasm a G IP levels, is PPARA . D eficiency of this nuclear receptor leads to d isturbed fatty  acids 
m etabolism  and prom otes H FD -induced hepatic lipids accum ulation and steatohepatitis.
4. D iscussion
In  recent years, m uch attention has been  paid to studying the role of incretin  horm ones in 
regulating metabolism, especially in the context of diabetes and obesity treatm ent, w ith more emphasis 
on GLP-1. However, it seem s that GIP is of significant im portance in the developm ent of obesity and 
its com plications, through interactions w ith  various bod y organs. The hypothesis w as raised that 
GIP signaling participates in the developm ent of hepatic steatosis [30]. Thus, our study aim ed to 
investigate w hether enhanced secretion of GIP in  obese hum ans m ay affect m arkers of liver injury, 
liver targeted FGFs, and plasm a m iRN A profile.
In  the presented study, fasting plasm a G IP values varied w idely  am ong studied 128 subjects 
w ith  excess bod y  w eight, correlated w ell w ith  postprandial G IP secretion, and w ere dichotom ized 
using 34 pg/mL (3rd tertile) as cut-off points to select "h igh  G IP " and "low  G IP " subjects. The above 
results h ighlight the disturbed postprandial glucose and triglycerides m etabolism  in h igh G IP  obese 
patients. Subjects w ith  low  GIP, despite obesity, seem ed to be insulin  sensitive and norm olipem ic. 
U nder physiological conditions, d iet-induced G IP action is beneficial for the physiology of adipose 
tissue prom oting the nutrient uptake in response to nutrient excess. G IP directly induces energy 
accum ulation in adipocytes by increasing lipoprotein lipase activity, stim ulation of lipogenesis, as well 
as by enhancing plasma mem brane GLUT4 expression and glucose uptake. Indirectly, GIP potentiates 
the anabolic action of insulin, w hich in total allows appropriate storage of nutrients and protects against 
lipotoxicity  [38] . H ow ever, several studies reported elevated G IP  levels in obese hum ans com pared 
w ith  lean hum ans [39] . Recently, G IP  (3-30) N H 2, a naturally  occurring peptide, w as show n to block 
the G IPR in hum ans and decrease GIP-induced insulin secretion as w ell as adipose tissue blood flow 
and TG  uptake [40]. K illion et al. [41] provided a preclinical validation of a therapeutic approach to 
treat obesity  w ith  anti-G IPR  antibodies. H ow ever, there is no agreem ent on w hether GIP receptor 
agonism or antagonism lowers body w eight [42] . Recently published in The Lancet, data from a phase 
II trial on dual hum an agonist with an im balance in favour of GIP agonism showed significantly better 
efficacy w ith  regard to w eight loss than did selective stim ulation of G LP-1 receptor [43,44]. Several 
studies have highlighted the direct relationship between overnutrition, increased levels of GIP, and the 
developm ent of obesity  and its selected m etabolic consequences including diabetes [17]. In hum an 
plasm a, G IP  levels are increased w ith  obesity and correlate w ith  body m ass index [39], b u t the exact 
role of G IP in the developm ent of obesity and diabetes is not fully understood and various concepts 
are suggested. Som e observations indicate that hyperglycem ia directly dow nregulates GIP receptors 
in beta cells, disturbing late-stage insulin release [45]. Increased postprandial GIP secretion positively 
correlates w ith  insulin  resistance, and chronic local and system ic inflam m ation, w hich m ay involve 
IL-6 signaling [46] . The obesity-associated inflam m atory state plays a key role in the developm ent of 
the hepatic steatosis.
Nutrients 2 0 2 0 ,12, 476 13 of 22
The present study dem onstrated that the p lasm a activity  of both  liver enzym es ALT and G G T 
as w ell as calculated  FLI, bu t not C K -18, w ere significantly  elevated in subjects w ith  high plasm a 
GIP levels. M artin-R odriguez et al. (2017) show ed a correlation of ALT w ith  liver fat content and 
increased insulin resistance, suggesting that ALT, even w hen w ithin the norm al range, m ay be useful 
for N A FLD  categorization w hen evaluating N A FLD 's system ic relationships. This study show s that 
optim al serum  ALT cut-off to predict N A FLD  is 23 IU/L [47], although there is no general consensus 
on the upper reference lim it of ALT (40 IU/l is the m ost com m on in  m edical practice). A  study on 
obese patients show ed that elevated ALT and G G T levels correlated significantly w ith  the incidence 
of steatohepatitis and fibrosis [48]. Fatty  liver index (FLI) w as developed as a sim ple and accurate 
predictor of hepatic steatosis in the general population of north Italy, and further, it has been validated 
on several European populations [21]. The large m ulticentre study show ed that FLI (like ALT), 
discrim inated betw een patients w ith and w ithout steatosis w ith an area under ROC (AUROC) of 0.79 
(inter-quartile range (IQ R) =  0.74, 0.84), accurately m atched the observed percentages of patients with 
hepatic steatosis, although it could n ot quantitatively  predict fatty liver disease [49] . The usefulness 
of C K -18 to differentiate betw een steatohepatitis and sim ple steatosis has been  reported in  m any 
studies [22,50,51]. C K -18 is a m ajor com ponent of interm ediate filam ents of hepatocytes, and the 
circulating fragm ent of CK-18 can specifically reflect the degree of hepatocellular apoptosis, w hich is 
a characteristic of N A SH . Thus, cytokeratin-18 (M 30) is a biom arker of disease severity in N A FLD , 
indicating progression to steatohepatitis [22] . In our study, increased ALT, GGT, and FLI associated 
w ith normal CK-18 (M30) suggest elevated risk for simple steatosis, but not steatohepatitis in high GIP 
subjects, w ithout sym ptom s of advanced hepatocytes apoptosis.
In  a previous study on d iabetic patients, h igher fasting GIP levels w ere also related to higher 
fasting and postprandial triglyceride levels and ALT [52].  The pathophysiology of N A FLD  includes 
(apart from  dietary fat contribution) proinflam m atory cytokines, hepatic and adipose tissue insulin 
resistance, lipotoxicity, and oxidative stress. A  reduced hepatic glucagon resistance, together w ith an 
impaired incretin effect, m ay be additional mechanism s [53] . Although the functional receptor for GIP 
(G IPR ) w as not found in the liver, this incretin horm one m ay play a role in hepatic steatosis exerting 
pleiotropic effects in other tissues. The group of M usso et al. [3 ] showed convincing results, indicating 
that G IP  response to saturated fatty  acids (SFA ) ingestion is prolonged in  non-diabetic patients w ith 
N A SH  and is correlated w ith  liver disease, an unfavorable dynam ic adipokine profile, and p cell 
dysfunction, w hich provides a rationale for GIP antagonism  in these subjects [3] . The results reported 
by Junker show ed that non-diabetic patients w ith  N A FLD  have norm al secretion of GIP and GLP-1, 
but a reduced incretin effect, although patients w ith cirrhosis have elevated concentrations of GIP and 
GLP-1, and a reduced incretin effect [54,55]. Recent papers underlie an im portant role of GIPR signaling 
in adipose tissue in HFD-induced insulin resistance and hepatic steatosis in vivo w ith no direct effect 
on fat accum ulation [30]. It w as show n that deletion of G IPR  signaling in  adipocytes results in  the 
decrease in interleukin (IL)-6 production in  adipose tissue and subsequent decrease in fat synthesis 
in the liver through the IL -6 -S O C S3-SR E B P -1c pathway. Insulin  resistance, liver w eight, hepatic 
steatosis, and body w eight, bu t not fa t volum e, w ere reduced in H FD -fed GIPRadipo-/- m ice [56]. 
D ata from  another study show  that G IP response to glucose absorption m ay play a role in  sucrose 
induced liver fat accum ulation by regulating the expression of Socs2 [57]. Moreover, central GIP related 
pathw ays are suggested to be involved in ep igenetic program m ing of peripheral gene expression 
related to a reduction of fatty acids oxidation, observed as increased m ethylation of prom oter of 
carnitine palm itoyltransferase gene (CPT1a) [58]. GIP acts in the brain by increasing the expression of 
the orexigenic hypothalamic neuropeptide Y (NPY) and by m odulating central AKT-mechanistic target 
of rapam ycin (mTOR) signaling, resulting in decreased fat oxidation in m uscle and fatty liver [2].
In  our study, am ong tw o liver targeted FGFs analyzed— FGF-19 and FGF-21— only FGF-21 w as 
found significantly associated w ith high circulating GIP. M eta-analysis of several studies provide clues 
about the role of FGF-21 as a key regulator of hepatic lipid m etabolism  in  hum ans and suggest that 
serum  FGF-21 can be used as a biom arker for N A FLD , being the m ost prom ising in  com bination
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w ith  other m arkers, such as C K -18 [24]. FGF-21 has m ultiple m etabolic actions in anim al m odels of 
obesity that include enhancing insulin sensitivity, decreasing triglyceride concentrations, and causing 
w eight loss. In lean rodents, FGF-21 expression is strongly induced in liver by prolonged fasting 
through peroxisom e proliferator-activated receptor gam m a coactivator protein-1alpha (PGC-1alpha). 
FG F-21, in turn, induces PG C -1alpha and stim ulates hepatic g luconeogenesis, fatty  acid oxidation, 
and ketogenesis, playing a key role in coordinating the adaptive starvation response [59]. Expression 
of FGF-21 is also upregulated postprandially  through peroxisom e proliferator-activated receptor 
gamma in white adipose tissue [60]. FGF-21 is known to increase metabolic flux and to reduce hepatic 
steatosis, but the m echanism s responsible for these effects are not fully discovered. The recent study 
on PG C -1alpha-deficient m ice revealed that, although FGF-21 effects such as stim ulation of physical 
activity  or energy expenditure depend on PG C -1alpha, the enhanced hepatic oxidative capacity  is 
m ediated by other transcription factors [61]. The genetic variability  of FGF-21 w as found to be 
potentially  associated w ith  m acronutrient consum ption, and risk of obesity  and type 2 d iabetes in 
hum ans [62]. Interestingly, in adipocytes, FGF-21 altered the expression of 18 secretory genes and 
enhanced by 1.15-fold the release of dipeptidyl peptidase IV (DPP IV)— the enzym e involved in  GIP 
(and GLP-1) inactivation [63]. This report raises the hypothesis that GIP secreted in response to meal 
ingestion, in the presence of high plasma FGF-21 concentration is quickly cleaved by DPP IV  and does 
not act properly. This relationship, together with results from our study, em phasize the im portance of 
an efficient gut-ad ip ose tissu e-liver axis.
Fibroblast grow th factor 19 functions m ainly as an  entero-hepatic signal to regulate b ile acids 
homeostasis (through inhibition of CYP7A1), and its deficiency im pairs liver regeneration in mice [64,65]. 
The FG F-19 has the ability  to m aintain  glucose hom eostasis through inhibition of gluconeogenesis, 
in the m echanism  involving inhibition of the cA M P response elem ent binding protein and P G C 1-a  
signaling cascade [66]. Conversely, adm inistration or overexpression of FG F-19 in m ice provided 
protection from diet-induced obesity as a result of increased hepatic fatty acid oxidation via suppression 
of acetyl-CoA carboxylase 2 and stearoyl-CoA desaturase 1 [67,68]. Furthermore, the circulating FGF-19 
concentration is reduced in  patients w ith  N A FLD , suggesting that dysregulated FGF-19 expression 
m ight contribute to the pathogenesis of N A FLD  [28,69] . Recently, in a randomized, placebo-controlled 
trial, an FGF-19 analogue, NGM 282, was shown to rapidly improve the liver fat content, independently 
of w eight loss and BM I, over 12 w eeks of treatm ent [70]. Significant im provem ents in  ALT, AST, 
and non-invasive serum  fibrosis biom arkers including pro-peptide of type III collagen and the total 
enhanced liver fibrosis score w ere also noticed  [70]. FG F-19 decreases bile acids secretion, including 
the ursodeoxycholic acid , w hich w as recently proved to increase G LP-1, bu t not GIP, secretion [71]. 
Thus FG F-19, though associated w ith  nutrient m etabolism , G LP-1 response, and insulin  sensitivity, 
seems not to be associated with plasma GIP levels, as confirm ed in our study. The metabolic functions 
of endocrine FG Fs can be regulated by m iRN A s. D ow nregulation of m iR-34a increases the levels of 
the FGF-21 receptor com ponents, resulting in FGF21/SIRT1-dependent induction of genes inducing 
brow ning of adipose tissue and im proved hepatic FGF-21 signaling and lipid oxidation [72].
In our study, besides the analysis of the association between plasma GIP levels and liver markers, 
we attempted to identify molecular mechanisms leading to liver damage in patients w ith im paired GIP 
signaling. For this purpose, w e com pared the plasm a m icroR N A  profile in obese patients w ith  high 
versus low plasma GIP levels. Analysis of the interactions of differentially expressed m icroRNAs with 
gene expression pathw ays suggests the potential contribution of selected m iRN A s to the regulation 
of the activity of genes associated w ith insulin resistance, fatty acids m etabolism , and adipocytokine 
(TN F-a, leptin) signaling. U pregulated m iRN A s in the h igh GIP group included m iR-136, m iR-320a, 
m iR-483, m iR-520d, m iR-520b, m iR-30e-3p, and m iR-571.
Enhanced inflam m atory cytokines expression and apoptosis w ere induced by m icroR N A -136 
through negative regulation of K lotho expression in H K -2 cells [73]. As K lotho inhibits N F -kB and 
W nt signaling pathw ays, over-expression of m iR-136 could reverse this inhibition [74] . O ther results 
indicate that m iR -136 acts by  targeting N F -k B signaling pathw ay to prom ote apoptosis in cervical
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carcinom a [75]. Thus, over-expression of m iR N A -136 m ay also be responsible for the upregulated 
N F -k B pathway found to be related to high plasma GIP levels [46]. Moreover, liver receptor homolog-1 
(LRH -1) w as identified as a d irect target gene of m iR-136 [75]. In the liver, LRH -1 w as established 
as a critical regulator of reverse cholesterol transport [76] as w ell as a crucial regulator of bile acid 
hom eostasis [77]. Thus, in  h igh GIP subjects, the m iR-136 over-expression m ay lead to dyslipidem ia 
and liver steatosis through suppression of LRH-1 expression.
We identified strongly upregulated miR-320a in high GIP versus low GIP subjects. Transcriptomic 
data from  m ice pancreatic tissue point to m iR-320 as the negative regulator of the m R N A  associated 
w ith  PI3K -A kt pathway, and hence d isturbed nutrient m etabolism  and diabetes [78]. Recently, it 
has been  docum ented that m iR -320 inhibits SIRT1 expression v ia targeting the 3 ' U TR  region of 
FoxM1 [79]. SIRT1 is the key sensor of metabolic states, w hich, in response to intracellular N A D+ levels, 
directly deacetylates and regulates transcription factors, such as P G C 1-a, PPARs, FOXO1, LXR, RXR, 
and SR EBPs, im portant for nutrient m etabolism . The role of adequate SIRT1 levels for proper liver 
function is well documented, as SIRT1 deletion results in hepatic steatosis and inflammation, and SIRT1 
activators im prove hepatosteatosis and insulin  resistance [80,81]. M icroRN A -320 m ay also regulate 
the developm ent of autophagy by  targeting hypoxia-inducible factor-1a  (H IF -1a) and m TO R under 
hypoxic conditions [82] . D ysregulation of the m TO R pathw ay— a key controller of lipid m etabolism , 
regulating lipogenesis in the liver, lipolysis in w hite adipose tissue, and adipogenesis— m ay prom ote 
liver steatosis and developm ent of N A FLD  [83].
W e found m iR-571 to be upregulated in  the h igh G IP group. Previously, m iR-571 has been 
described as being associated w ith type 2 diabetes as well as significantly correlated w ith m icrovascular 
com plications of diabetes [84] . M oreover, alterations of serum  m iR-571 levels in patients w ith chronic 
liver disease and its up-regulation in hum an hepatocytes and hepatic stellate cells in response to the 
pro-fibrogenic cytokine TGF-p reflected their putative roles as a mediator of fibrogenic and inflammatory 
processes in distinct cellular com partm ents involved in the pathogenesis of liver cirrhosis [85].
In  our study, m iR -520d-5p w as upregulated in  high G IP patients. A  luciferase reporter assay 
revealed binding sites for miR-520d-5 on TEA domain transcription factor 1 (TEAD1) target gene [86]. It 
has been proven recently that knockdown of TEAD1 decreases the expression of P G C 1a and suppresses 
m itochondrial biogenesis, g lycolysis, and oxygen consum ption in  endothelial cells [87]. R educing 
the num ber of active m itochondria and slow ing down the rate of m itochondrial oxidation as a result 
of dow n-regulation of TEA D 1 and P G C 1-a  m ay contribute to d isturbed fatty  acid catabolism , and 
consequently to the developm ent of fatty liver in high GIP patients.
The present study revealed significantly lower miR-328 expression in high GIP patients compared 
w ith  the low  G IP group. In  the experim ental m odel of osteosarcom a cells, the inverse relationship 
betw een m iR-328 and M M P-2 expression w as found and inhibition of m iR -328 resulted in the 
enhanced production of M M P-2 [88]. U pregulation of m iR-328 repressed the expression of TG F-p2 
and extracellular m atrix (ECM) proteins and prevented renal fibrogenesis [89]. Enhanced production 
of m atrix m etalloproteinases, including M M P-2, and ECM  proteins m ay lead to tissue rem odeling, as 
w ell as in the liver. A recent study indicates that m iR-328-3p targets GLUT1, leading to a significantly 
low er glucose uptake and decline in intracellular levels of glucose and lactate [90] . Consequently, a 
significant m iR-328-3p deficiency m ay increase nutrient uptake, essential for liver steatosis.
Previous studies on mice or rat models showed other microRNAs, including m iRNA-27a, miR-29, 
miR-122, miR-132, m iR-150, and miR-181b, to be involved in regulating hepatic lipids' m etabolism  and 
to be associated w ith liver steatohepatitis [91- 94]. Other reports indicate m iR-34a, m iR-335, miR-33a/b, 
miR-143, and miR-103/107 as those that target liver, as reviewed by Rottiers et al. [95] and Dongiovanni 
et al. [32] . The above types of m icroRN A s, as w ell as m icroRN A s characteristic for obesity, w ere not 
identified in our study as differentially expressed in high GIP subjects. The m ost likely reasons are that 
all of our studied subjects were com parable according to BM I and body fat content, as w ell as the fact 
that they did not have a clinically diagnosed liver disease.
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The incretin hormones can m odulate the expression of miRNAs, although m ost of the data concern 
G LP-1 not GIP. G LP-1 w as found to upregulate m iR-758, m iR-27a, m iR-192, m iR-212, and m iR-132 
and dow nregulate m iR-23 and m iR -375 [34]. Both up and dow n regulation result in a reduction 
of b lood glucose by im proving beta-cell function and increasing insulin  secretion. Little is know n 
about regulation of m iRN A  expression by GIP, though there is a report on overexpression of m iR-375 
stim ulated also by  G IP [96]. The authors suggest that this circulating m iRN A  m ay originate from  
enteroendocrine cells or the brain, and could exert a diverse effect on lipid and glucose m etabolism  in 
the liver. Thus, circulating levels of m iRN A  m ay respond to signaling m olecules released by the gut, 
but further experim ental studies are w arranted.
The main lim itation of our study is the lack of liver imaging data, which would allow us to assess 
the level of liver steatosis in obese patients. The multiparametric capability of ultrasonography and M R 
im aging obviously gives high diagnostic perform ance tow ards liver injury, and these tests should be 
taken into account w hen planning further studies on GIP as a prognostic factor for NAFLD. However, 
our objective w as to elucidate how  high circulating G IP m ay influence factors contributing to the 
developm ent of fatty liver disease. Thus, w e focused on the g u t-liv er axis, especially  liver-targeted 
FGFs and m icroR N A s as potent m echanism s of the inter-organ crosstalk. A nother lim itation of our 
study is the sm all num ber of sam ples available for m iRN A  profiling. N evertheless, w e m ade an 
attempt to carry out m iRN A analysis in subjects representative for both high GIP and low GIP groups, 
in accordance w ith m ost current guidelines [36]. For this reason, we suggest that miRNAs differentially 
expressed, according to circulating GIP, in our study, should be validated on a larger group of subjects. 
C irculating m iRN A s originate from  death cells or from  m icrovesicles that are actively released from  
cells. Future studies should also analyze the d istribution of m iRN A s in  the different com partm ents, 
protein versus vesicles, that could provide additional inform ation regarding the identification of a 
specific m iRN A pattern associated w ith disturbed GIP signaling.
5. Conclusions
Overall, in the current study, we indicate that exaggerated fasting and postprandial GIP secretion 
in obesity is associated w ith  elevated ALT, GGT, FLI, as w ell as FGF-21 plasm a levels. D ifferentially 
expressed m icroRNAs suggest additional, epigenetic factors, contributing to the developm ent of liver 
steatosis in patients w ith impaired GIP signaling. Understanding how high plasma GIP levels influence 
liver m ay help to elucidate potentially  biological m echanism s for determ ining treatm ent strategies 
and prognosis.
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